ENDRA Life Sciences Inc.
NDRAHealthcareNASDAQDiagnostics & Research
Scan Results
Daily timeframeHeadquartered within the healthcare sector, ENDRA Life Sciences Inc. focuses on Diagnostics & Research services and products. ENDRA Life Sciences Inc. develops technologies to improve the capabilities of clinical diagnostic ultrasound. Valued at $9.1M, NDRA is a micro-cap name in its sector. The company is involved in the development of thermo-acoustic enhanced ultrasound technology that uses pulsed energy source such as radio frequency to transmit energy deep into tissue and generate ultrasonic waves to create high-contrast images for use in the treatment of non-alcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion analysis.
Market Cap
$9.1M
Beta
-0.04
P/E (TTM)
—
P/E (Fwd)
-1.99
EPS (TTM)
$-6.29
EPS (Fwd)
$-3.04
ROE
-152.0%
ROA
-77.3%
Cash
$1.7M
Total Debt
$429,274
Free CF
-$6.7M
52W Change
45.4%
Annual Financials
Cash vs Debt
Where NDRA stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, NDRA finished 39.52% above its 150-day moving average ($4.63) and 35.71% above its 200-day moving average ($4.76). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is NDRA overbought or oversold?
At the September 3, 2026 close, NDRA's RSI(14) was 82.6, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $1.7M in cash comfortably exceeding the $429K debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$6.7M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -152.0% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
NDRA's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence ENDRA Life Sciences Inc.'s trajectory.